High 'continuation' rate could mean a cascading price cut

July 6, 2020 Latest News

This is a preview of subscriber content

Subscribe now to continue reading.

The newly-released Public Summary Document shows the PBAC acknowledging the efficacy and strong support for the listing of Sanofi's DUPIXENT (dupilumab) for severe atopic dermatitis but also its focus on the potential mix of new and continuing patients. …

Subscribe now to continue reading.

Latest Video

Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - Latest News
Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse
September 21, 2026 - Australian Biotech
Officials are using AI to create efficiencies in the HTA evaluation process
September 21, 2026 - Latest News
New AI contribution tool delivers 150 patient voices to the PBAC
September 21, 2026 - Latest News
Treasury has moved on from the PBS, but the policies built on its error have not
September 21, 2026 - Latest News

High 'continuation' rate could mean a cascading price cut

This is a preview of subscriber content

Latest Video

Most Read

Given the official use of AI, a cease and desist would not be unreasonable

Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse

Officials are using AI to create efficiencies in the HTA evaluation process

New AI contribution tool delivers 150 patient voices to the PBAC

Treasury has moved on from the PBS, but the policies built on its error have not

New Stories

Medicines Australia seeks answers on AI in HTA process

The prevention gap and inside Sally Panton's bet on cellular health

Pfizer 'deeply disappointed' in response to PBAC refusing to move on price

Lilly goes direct with a patient platform for its non-PBS medicines

A 'multistakeholder' reference group to shadow agreement negotiations

If there is a productivity gain in the process, then it should be passed on

Given the official use of AI, a cease and desist would not be unreasonable

Sign In

High 'continuation' rate could mean a cascading price cut

This is a preview of subscriber content

Latest Video

Most Read

Given the official use of AI, a cease and desist would not be unreasonable

Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse

Officials are using AI to create efficiencies in the HTA evaluation process

New AI contribution tool delivers 150 patient voices to the PBAC

Treasury has moved on from the PBS, but the policies built on its error have not

Follow Us

New Stories

Medicines Australia seeks answers on AI in HTA process

The prevention gap and inside Sally Panton's bet on cellular health

Pfizer 'deeply disappointed' in response to PBAC refusing to move on price

Lilly goes direct with a patient platform for its non-PBS medicines

A 'multistakeholder' reference group to shadow agreement negotiations

If there is a productivity gain in the process, then it should be passed on

Given the official use of AI, a cease and desist would not be unreasonable